{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:45:56Z","timestamp":1794026756770,"version":"4.8.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T00:00:00Z","timestamp":1543708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Immunology Research Center, Tabriz University of Medical Sciences"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.biopha.2018.12.009","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:08:55Z","timestamp":1544789335000},"page":"857-868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"special_numbering":"C","title":["Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-5555","authenticated-orcid":false,"given":"Sanam","family":"Nami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Aghebati-Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-0035","authenticated-orcid":false,"given":"Hamid","family":"Morovati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leili","family":"Aghebati-Maleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.12.009_bib0005","series-title":"Candida and Candidiasis","author":"Calderone","year":"2011"},{"issue":"Suppl. 2","key":"10.1016\/j.biopha.2018.12.009_bib0010","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1093\/jac\/dkw392","article-title":"The current treatment landscape: candidiasis","volume":"71","author":"Bassetti","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"issue":"15","key":"10.1016\/j.biopha.2018.12.009_bib0015","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0020","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.idc.2006.07.004","article-title":"Invasive candidiasis","volume":"20","author":"Pappas","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00134-014-3310-z","article-title":"A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality","volume":"40","author":"Bassetti","year":"2014","journal-title":"Intensive Care Med."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0030","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00134-015-3866-2","article-title":"A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality","volume":"41","author":"Bassetti","year":"2015","journal-title":"Intensive Care Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1099\/jmm.0.000402","article-title":"Invitro antifungal susceptibilities of Candida species to liposomal amphotericin B, determined using CLSI broth microdilution, and amphotericin B deoxycholate, measured using the Etest","volume":"66","author":"Lovero","year":"2017","journal-title":"J. Med. Microbiol."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0040","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/13543784.2017.1341488","article-title":"Drugs currently under investigation for the treatment of invasive candidiasis","volume":"26","author":"McCarthy","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2018.12.009_bib0045","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/JCM.43.11.5425-5427.2005","article-title":"In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole","volume":"43","author":"Pfaller","year":"2005","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0050","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1128\/JCM.41.1.78-83.2003","article-title":"In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood","volume":"41","author":"Pfaller","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0055","series-title":"Fungal Infection: Diagnosis and Management","author":"Richardson","year":"2012"},{"key":"10.1016\/j.biopha.2018.12.009_bib0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12539","article-title":"Global trends in the distribution of Candida species causing candidemia","volume":"20","author":"Guinea","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0065","doi-asserted-by":"crossref","first-page":"e101510","DOI":"10.1371\/journal.pone.0101510","article-title":"Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004\u20132008","volume":"9","author":"Pfaller","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1086\/321811","article-title":"Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study","volume":"33","author":"Blumberg","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0075","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00134-014-3355-z","article-title":"Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later","volume":"40","author":"Eggimann","year":"2014","journal-title":"Intensive Care Med."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s10096-016-2658-0","article-title":"Invasive candidiasis: from mycobiome to infection, therapy, and prevention","volume":"35","author":"Lagunes","year":"2016","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"21","key":"10.1016\/j.biopha.2018.12.009_bib0085","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1001\/jama.2009.1754","article-title":"International study of the prevalence and outcomes of infection in intensive care units","volume":"302","author":"Vincent","year":"2009","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0090","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s10096-007-0270-z","article-title":"Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting","volume":"26","author":"Ostrosky-Zeichner","year":"2007","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0095","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/cid\/cit006","article-title":"Finding the \u201cmissing 50%\u201d of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care","volume":"56","author":"Clancy","year":"2013","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0100","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/infdis\/125.2.190","article-title":"Problems in the diagnosis and treatment of systemic candidiasis","volume":"125","author":"Goldstein","year":"1972","journal-title":"J. Infect. Dis."},{"issue":"suppl_3","key":"10.1016\/j.biopha.2018.12.009_bib0105","doi-asserted-by":"crossref","first-page":"S445","DOI":"10.1093\/infdis\/jix131","article-title":"Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment","volume":"216","author":"Arendrup","year":"2017","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0110","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin. Infect. Dis."},{"issue":"93","key":"10.1016\/j.biopha.2018.12.009_bib0115","article-title":"Comparision of antifungal effect of fluconazole alone and in combination with nanosilver particles against candida species isolated from chronic candidal vulvovaginitis","volume":"18","author":"Nozari","year":"2012","journal-title":"Razi J. Med. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0120","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/13693780601164306","article-title":"Candida krusei sepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient","volume":"45","author":"Westbrook","year":"2007","journal-title":"Med. Mycol."},{"issue":"18","key":"10.1016\/j.biopha.2018.12.009_bib0125","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1056\/NEJM199110313251803","article-title":"Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole","volume":"325","author":"Wingard","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0130","doi-asserted-by":"crossref","first-page":"e00189","DOI":"10.1128\/mSphere.00189-16","article-title":"Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species","volume":"1","author":"Borman","year":"2016","journal-title":"MSphere"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jinf.2016.07.008","article-title":"First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia","volume":"73","author":"Calvo","year":"2016","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2018.12.009_bib0140","series-title":"Emergence of Candida auris: An International Call to Arms","author":"Clancy","year":"2016"},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0145","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1128\/JCM.00367-15","volume":"53","author":"Kathuria","year":"2015","journal-title":"J. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0150","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ajt.14121","article-title":"Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug\u2010resistant fungus\u2014United States, May 2013\u2013August 2016","volume":"17","author":"Vallabhaneni","year":"2017","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0155","first-page":"249","article-title":"Oral Candida infection and colonization in solid organ transplant recipients","volume":"24","author":"Dongari\u2010Bagtzoglou","year":"2009","journal-title":"Mol. Oral Microbiol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0160","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0165","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1128\/AAC.01144-13","article-title":"Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure","volume":"57","author":"Lewis","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0170","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1128\/AAC.03255-14","article-title":"Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance","volume":"58","author":"Pham","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2018.12.009_bib0175","series-title":"Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data from a Large Multisite Population-Based Candidemia Surveillance Program, 2008\u20132014. Open Forum Infectious Diseases","year":"2015"},{"issue":"Supplement_1","key":"10.1016\/j.biopha.2018.12.009_bib0180","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1093\/clinids\/14.Supplement_1.S161","article-title":"Azole antifungal agents","volume":"14","author":"Bodey","year":"1992","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0185","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1128\/CMR.12.1.40","article-title":"Current and emerging azole antifungal agents","volume":"12","author":"Sheehan","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1093\/jac\/dki473","article-title":"Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?","volume":"57","author":"Charlier","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.biopha.2018.12.009_bib0195","series-title":"Treatment of Candidemia and Invasive Candidiasis in Adults","author":"Kauffman","year":"2012"},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0200","doi-asserted-by":"crossref","first-page":"e59373","DOI":"10.1371\/journal.pone.0059373","article-title":"Epidemiology of candidemia in Latin America: a laboratory-based survey","volume":"8","author":"Nucci","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.12.009_bib0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0210","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00134-008-1339-6","article-title":"Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part II. Treatment","volume":"35","author":"Guery","year":"2009","journal-title":"Intensive Care Med."},{"issue":"9495","key":"10.1016\/j.biopha.2018.12.009_bib0215","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/S0140-6736(05)67490-9","article-title":"Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial","volume":"366","author":"Kullberg","year":"2005","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.biopha.2018.12.009_bib0220","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0225","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1086\/374850","article-title":"A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects","volume":"36","author":"Rex","year":"2003","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0230","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0235","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1097\/INF.0b013e31819f1f50","article-title":"Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants","volume":"28","author":"Wade","year":"2009","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0240","doi-asserted-by":"crossref","first-page":"53","DOI":"10.15171\/apb.2017.007","article-title":"The utilization of RNA silencing technology to mitigate the voriconazole resistance of aspergillus flavus; lipofectamine-based delivery","volume":"7","author":"Nami","year":"2017","journal-title":"Adv. Pharm. Bull."},{"issue":"11","key":"10.1016\/j.biopha.2018.12.009_bib0245","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10096-003-1014-3","article-title":"Voriconazole salvage treatment of invasive candidiasis","volume":"22","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0250","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/524669","article-title":"Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes","volume":"46","author":"Pascual","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"20","key":"10.1016\/j.biopha.2018.12.009_bib0255","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1056\/NEJM199411173312001","article-title":"A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia","volume":"331","author":"Rex","year":"1994","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0260","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1086\/380796","article-title":"Guidelines for treatment of candidiasis","volume":"38","author":"Pappas","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0265","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1086\/499057","article-title":"Current treatment strategies for disseminated candidiasis","volume":"42","author":"Spellberg","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0270","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00277-003-0666-5","article-title":"Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution","volume":"82","author":"Lass-Fl\u00f6rl","year":"2003","journal-title":"Ann. Hematol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0275","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.PCC.0000144712.29127.81","article-title":"Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study","volume":"5","author":"Mondal","year":"2004","journal-title":"Pediatr. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0280","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1128\/AAC.49.2.783-787.2005","article-title":"Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole","volume":"49","author":"Borst","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1128\/CMR.00029-06","article-title":"Epidemiology of invasive candidiasis: a persistent public health problem","volume":"20","author":"Pfaller","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0290","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1128\/JCM.42.7.3142-3146.2004","article-title":"Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002","volume":"42","author":"Pfaller","year":"2004","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0295","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1128\/AAC.44.6.1585-1587.2000","article-title":"Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?","volume":"44","author":"Goldman","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"5","key":"10.1016\/j.biopha.2018.12.009_bib0300","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.mib.2006.08.001","article-title":"Clinical efficacy of new antifungal agents","volume":"9","author":"Kauffman","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0305","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.40.4.1298-1302.2002","article-title":"Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study","volume":"40","author":"Diekema","year":"2002","journal-title":"J. Clin. Microbiol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0310","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2018.12.009_bib0315","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: a broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0320","article-title":"Posaconazole (POS) as Salvage Therapy for Invasive Fungal Infections Unresponsive to Voriconazole: A Case Series","year":"2004","journal-title":"44th Interscience Conference on Antimicrobial Agents and Chemotherapy"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0325","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.12.009_bib0330","first-page":"163","article-title":"Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections","volume":"6","author":"Falci","year":"2013","journal-title":"Infect. Drug Resist."},{"issue":"10020","key":"10.1016\/j.biopha.2018.12.009_bib0335","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"9390","key":"10.1016\/j.biopha.2018.12.009_bib0340","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0345","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1128\/AAC.00473-08","article-title":"Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection","volume":"52","author":"Thompson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0350","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/JCM.02390-09","article-title":"Breakthrough invasive candidiasis in patients on micafungin","volume":"48","author":"Pfeiffer","year":"2010","journal-title":"J. Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0355","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0149-2918(02)85039-1","article-title":"Caspofungin: an echinocandin antifungal agent","volume":"24","author":"Stone","year":"2002","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0365","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/jac\/dkm169","article-title":"Caspofungin for the treatment of less common forms of invasive candidiasis","volume":"60","author":"Cornely","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0370","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.46.2.451-457.2002","article-title":"Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases","volume":"46","author":"Arathoon","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0375","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1034\/j.1399-3062.2002.01004.x","article-title":"Safety and tolerability of caspofungin acetate in the treatment of fungal infections","volume":"4","author":"Sable","year":"2002","journal-title":"Transpl. Infect. Dis."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0380","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1086\/323401","article-title":"A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis","volume":"33","author":"Villanueva","year":"2001","journal-title":"Clin. Infect. Dis."},{"issue":"25","key":"10.1016\/j.biopha.2018.12.009_bib0385","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa021585","article-title":"Comparison of caspofungin and amphotericin B for invasive candidiasis","volume":"347","author":"Mora-Duarte","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.biopha.2018.12.009_bib0390","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1097\/01.inf.0000145408.51526.0a","article-title":"Caspofungin therapy of neonates with invasive candidiasis","volume":"23","author":"Odio","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0395","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/501020","article-title":"Micafungin: a new echinocandin","volume":"42","author":"Chandrasekar","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0400","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/JCM.01901-07","article-title":"In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance","volume":"46","author":"Pfaller","year":"2008","journal-title":"J. Clin. Microbiol."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0405","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0410","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0415","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1128\/AAC.47.9.2717-2724.2003","article-title":"Disruption of ergosterol biosynthesis confers resistance to amphotericin B in Candida lusitaniae","volume":"47","author":"Young","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0420","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/jac\/49.suppl_1.7","article-title":"Amphotericin B: spectrum and resistance","volume":"49","author":"Ellis","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0425","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1086\/500939","article-title":"Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient","volume":"42","author":"Krogh-Madsen","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0430","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin b as initial therapy for invasive mold infection: a randomized trial comparing a high\u2013loading dose regimen with standard dosing (AmBiLoad Trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1365-2141.1998.00944.x","article-title":"Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia\u2010associated invasive fungal infections","volume":"103","author":"Leenders","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.biopha.2018.12.009_bib0440","first-page":"CD010481","article-title":"Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function","volume":"23","author":"Botero","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"9572","key":"10.1016\/j.biopha.2018.12.009_bib0445","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0450","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.biopha.2018.12.009_bib0455","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0460","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1634\/theoncologist.5-2-120","article-title":"New drugs and novel targets for treatment of invasive fungal infections in patients with cancer","volume":"5","author":"Chiou","year":"2000","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.biopha.2018.12.009_bib0465","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrd3074","article-title":"An insight into the antifungal pipeline: selected new molecules and beyond","volume":"9","author":"Ostrosky-Zeichner","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0470","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/AAC.00999-10","article-title":"Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0475","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.smim.2006.12.004","article-title":"TLR signaling","volume":"19","author":"Kawai","year":"2007","journal-title":"Semin. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0480","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nri2765","article-title":"The SYK tyrosine kinase: a crucial player in diverse biological functions","volume":"10","author":"M\u00f3csai","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.biopha.2018.12.009_bib0485","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nri3897","article-title":"Immune defence against Candida fungal infections","volume":"15","author":"Netea","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2018.12.009_bib0490","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0495","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.virol.2015.02.051","article-title":"PRRs are watching you: localization of innate sensing and signaling regulators","volume":"479\u2013480","author":"Chow","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.biopha.2018.12.009_bib0500","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1084\/jem.20050678","article-title":"Aberrant T cell differentiation in the absence of Dicer","volume":"202","author":"Muljo","year":"2005","journal-title":"J. Exp. Med."},{"issue":"7103","key":"10.1016\/j.biopha.2018.12.009_bib0505","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nature04926","article-title":"Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity","volume":"442","author":"Gross","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0510","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.12.009_bib0515","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.biopha.2017.07.160","article-title":"Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy","volume":"95","author":"Valedkarimi","year":"2017","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nri1255","article-title":"Immunity to fungal infections","volume":"4","author":"Romani","year":"2004","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2018.12.009_bib0525","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3109\/08820139.2015.1093913","article-title":"Immunotherapy of fungal infections","volume":"44","author":"Datta","year":"2015","journal-title":"Immunol. Invest."},{"key":"10.1016\/j.biopha.2018.12.009_bib0530","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2018.12.009_bib0535","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1086\/322710","article-title":"Adjunctive immune therapy for fungal infections","volume":"33","author":"Casadevall","year":"2001","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0540","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood.V81.7.1883.1883","article-title":"The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis","volume":"81","author":"Bensinger","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.12.009_bib0545","first-page":"175","article-title":"Epidemiology and treatment approaches in management of invasive fungal infections","volume":"3","author":"Kriengkauykiat","year":"2011","journal-title":"Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.biopha.2018.12.009_bib0550","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14712598.2017.1322576","article-title":"Promising immunotherapy against fungal diseases","volume":"17","author":"Posch","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0555","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"issue":"19","key":"10.1016\/j.biopha.2018.12.009_bib0560","doi-asserted-by":"crossref","first-page":"10942","DOI":"10.1073\/pnas.1731272100","article-title":"Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection","volume":"100","author":"Dadachova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2018.12.009_bib0565","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1086\/503428","article-title":"A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibodybased inhibitor of heat shock protein 90 in patients with invasive candidiasis","volume":"42","author":"Pachl","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0570","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1128\/AAC.01324-10","article-title":"Dose range evaluation of Mycograb C28Y variant, a human recombinant antibody fragment to heat shock protein 90, in combination with amphotericin Bdesoxycholate for treatment of murine systemic candidiasis","volume":"55","author":"Louie","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.biopha.2018.12.009_bib0575","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1201-9712(02)90104-9","article-title":"Cytokines in immunodeficient patients with invasive fungal infections: an emerging therapy","volume":"6","author":"Roilides","year":"2002","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0580","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.4049\/jimmunol.169.10.5787","article-title":"CD8 T cellmediated killing of Cryptococcus neoformans requires granulysin and is dependent on CD4 T cells and IL-15","volume":"169","author":"Ma","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0585","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.coi.2014.01.014","article-title":"Vaccine immunity against fungal infections","volume":"28","author":"Nanjappa","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0590","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","article-title":"Adjunctive interferon-gamma immunotherapy for the treatment of HIVassociated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.biopha.2018.12.009_bib0595","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant interferongamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis","volume":"189","author":"Pappas","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0600","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1182\/blood-2010-12-325084","article-title":"Crossprotective TH1 immunity against Aspergillus fumigatus and Candida albicans","volume":"117","author":"Stuehler","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.12.009_bib0605","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.biopha.2017.01.070","article-title":"Receptor tyrosine kinase-like orphan receptor 1 (ROR-1): an emerging target for diagnosis and therapy of chronic lymphocytic leukemia","volume":"88","author":"Aghebati-Maleki","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2018.12.009_bib0610","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/1359-6101(96)00019-6","article-title":"Long pentraxins: an emerging group of proteins with diverse functions","volume":"7","author":"Goodman","year":"1996","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.biopha.2018.12.009_bib0615","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2010-12-322610","article-title":"Generation of a multipathogenspecific T-cell product for adoptive immunotherapy based on activation-dependent expression of CD154","volume":"118","author":"Khanna","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.12.009_bib0620","doi-asserted-by":"crossref","first-page":"10660","DOI":"10.1073\/pnas.1312789111","article-title":"Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection","volume":"111","author":"Kumaresan","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2018.12.009_bib0625","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.3389\/fimmu.2017.01939","article-title":"Methods of controlling invasive fungal infections using CD8+ T cells","volume":"8","author":"Kumaresan","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0630","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bcmd.2007.06.016","article-title":"Provision of antifungal immunity and concomitant alloantigen tolerization by conditioned dendritic cells in experimental hematopoietic transplantation","volume":"40","author":"Montagnoli","year":"2008","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0635","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1182\/blood-2003-03-0748","article-title":"A dendritic cell vaccine against invasive aspergillosis inallogeneic hematopoietic transplantation","volume":"102","author":"Bozza","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2018.12.009_bib0640","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.4049\/jimmunol.0803462","article-title":"Early NK cell-derived IFN-{gamma} is essential to host defense in neutropenic invasive aspergillosis","volume":"182","author":"Park","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2018.12.009_bib0645","doi-asserted-by":"crossref","first-page":"e1006154","DOI":"10.1371\/journal.ppat.1006154","article-title":"Neutrophil interactions stimulate evasive hyphal branching by Aspergillus fumigatus","volume":"13","author":"Ellett","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2018.12.009_bib0650","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2567.2009.03112.x","article-title":"Impaired macrophage function following bacterial stimulation in chronic granulomatous disease","volume":"128","author":"Rahman","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.biopha.2018.12.009_bib0655","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000369493","article-title":"Effective neutrophil phagocytosis of Aspergillus fumigatus is mediated by classical pathway complement activation","volume":"7","author":"Braem","year":"2015","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.biopha.2018.12.009_bib0660","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/cncr.20883","article-title":"The safety of interferon-gamma-1b therapy for invasive fungal infections after hematopoietic stem cell transplantation","volume":"103","author":"Safdar","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2018.12.009_bib0665","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1086\/652496","article-title":"Safety and efficacy of activated transfected killer cells for neutropenic fungal infections","volume":"201","author":"Lin","year":"2010","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2018.12.009_bib0670","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1590\/0074-02760150335","article-title":"New insights on the development of fungal vaccines: from immunity to recent challenges","volume":"110","author":"Medici","year":"2015","journal-title":"Mem. Inst. Oswaldo Cruz"},{"issue":"Suppl. 1","key":"10.1016\/j.biopha.2018.12.009_bib0675","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/j.bbmt.2010.09.008","article-title":"Chronic granulomatous disease: lessons from a rare disorder","volume":"17","author":"Segal","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"6","key":"10.1016\/j.biopha.2018.12.009_bib0680","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1365-3083.2008.02101.x","article-title":"Antifungal immunotherapy and immunomodulation: a double\u2010hitter approach to deal with invasive fungal infections","volume":"67","author":"Hamad","year":"2008","journal-title":"Scand. J. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.009_bib0685","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12929-016-0285-9","article-title":"Phage display as a promising approach for vaccine development","volume":"29;23","author":"Aghebati-Maleki","year":"2016","journal-title":"J. Biomed. Sci."},{"issue":"7685","key":"10.1016\/j.biopha.2018.12.009_bib0690","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1038\/d41586-017-08702-7","article-title":"Combinations on trial","volume":"552","author":"Schmidt","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2018.12.009_bib0695","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2217\/imt.12.127","article-title":"Immune modulators as adjuncts for the prevention and treatment of invasive fungal infections","volume":"4","author":"Pikman","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.biopha.2018.12.009_bib0700","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.biopha.2018.10.075","article-title":"Fungal vaccines, mechanism of actions and immunology: a comprehensive review","volume":"109","author":"Nami","year":"2019","journal-title":"Biomed. Pharmacother."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218350765?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218350765?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T21:20:30Z","timestamp":1764105630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218350765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":140,"alternative-id":["S0753332218350765"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.009","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current antifungal drugs and immunotherapeutic approaches as promising strategies to treatment of fungal diseases","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}